NCT04141150 - Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

February 28, 2025

Conditions

Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy Volunteers

Interventions

DRUG

[18F]APN-1607

In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

Trial Locations (3)

10032

Columbia University Irving Center for Clinical and Translational Research (Site 105), 622 West 168th Street, PH-10th Floor, New York

06510

Invicro (Site 100), 60 Temple Street, 8th Floor, New Haven

07856

The NeuroCognitive Institute (Site 103), 111 Howard Blvd., Suite 204, Mount Arlington